Palvella Therapeutics, Inc. Share Price (NASDAQ: PVLA)

Palvella Therapeutics, Inc. Stock Performance

as on October 16, 2025 at 1:29 am IST

Day's Low
Day's High
$73.55
Day's Price Range
$77.67
$76.34
3.65%
Downside
1.74%
Upside
52 Week's Low
52 Week's High
$11.17
52-Week Price Range
$77.67
$76.34
85.37%
Downside
1.74%
Upside

Palvella Therapeutics, Inc. share price movements today

Previous Close: $73.52
Open: $74.12
Volume: 309.0K
Day's Low - High: $73.55 - $77.67
52 Week Low - High: $11.17 - $77.67

Palvella Therapeutics, Inc. Historical Returns

1 Month Return: + 39.99 %
3 Month Return: + 168.51 %
1 Year Return: 0 %
3 Year Return: 0 %
5 Year Return: 0 %

Palvella Therapeutics, Inc. Stock Fundamentals & Key Indicators

Check Palvella Therapeutics, Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$813.1M

EPS (TTM)

-3.2591

Dividend Yield

0.00%

PE Ratio (TTM)

PEG Ratio

Return On Equity TTM

31773600.00%

Palvella Therapeutics, Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Palvella Therapeutics, Inc. with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %
Palvella Therapeutics, Inc.	NA	$813.1M	NA	NA	0.00%
Alnylam Pharmaceuticals, Inc.	BUY	$61.5B	223.43%	-505.15	-12.96%
Beone Medicines Ltd	NA	$37.1B	NA	NA	-3.89%
Vertex Pharmaceuticals Incorporated	BUY	$105.7B	87.04%	28.99	31.86%
Regeneron Pharmaceuticals, Inc.	BUY	$59.6B	-3.89%	14.07	31.37%

Palvella Therapeutics, Inc. Stock’s Investor Sentiment and Interest

Search interest for Palvella Therapeutics, Inc. Stock has increased by 317% in the last 30 days, reflecting an upward trend in search activity.

Time period: September 16, 2025 to October 16, 2025

Change:317% versus previous 30 day period

Palvella Therapeutics, Inc. Quarterly Profit & Loss

All numbers in Millions USD

	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Mar 2025	Jun 2025
Total Revenue	5	1	20	19	1	0	-	-	-
Gross Profit	5	1	19	18	1	-	-	-	-
Operating Income	-11	-15	2	3	-5	-1	-4	-7	-9
EBITDA	-7	-12	4	-10	-4	-1	-3	-6	-8
Interest Expense	-	2	-	-	-	0	1	1	1
Depreciation	-	-	-	-	-	-	-	-	-
Income Before Tax	-8	-13	3	-10	-4	-2	-3	-8	-9
Income Tax Expense	-	-	-	-	-	-	-	-	-
Net Income	-8	-13	3	-10	-4	-2	-3	-8	-9
Net Profit Margin	-138.59%	-680.94%	19.83%	-55.08%	-352.89%	-4784.91%	0.00%	0.00%	0.00%

Palvella Therapeutics, Inc. Annual Profit & Loss

All numbers in Millions USD

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Revenue	2	5	25	29	46	29	31	25	-	-
Gross Profit	-	-	-	-	-	29	29	23	-	-
Operating Income	-13	-22	-14	-30	-27	-33	-51	-43	-11	-14
EBITDA	-13	-22	-16	-26	-24	-34	-43	-30	18	-13
Interest Expense	-	-	-	-	-	-	-	-	-	4
Depreciation	-	-	-	-	-	-	-	-	-	-
Income Before Tax	-13	-22	-16	-27	-25	-37	-45	-33	18	-17
Income Tax Expense	0	0	1	0	-	0	-	-1	-	-
Net Income	-14	-22	-17	-26	-25	-37	-45	-33	18	-17
Net Profit Margin	-479.50%	-391.00%	-69.82%	-91.93%	-55.03%	-126.97%	-145.58%	-128.47%	0.00%	0.00%

Palvella Therapeutics, Inc. Quarterly Cash Flow

All numbers in Millions USD

	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Dec 2024	Mar 2025	Jun 2025
Net Income	-10	-4	-2	-4	-3	-8	-9
Operating Cash Flow	-9	-19	-1	-1	-	-6	-5
Investing Cash Flow	-1	3	-	-	-	-	-
Financing Cash Flow	-	0	-	9	-	-1	0
Change in Cash	-12	-15	-1	8	-	-7	-5

Palvella Therapeutics, Inc. Annual Cash Flow

All numbers in Millions USD

	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Net Income	-45	-27	18	-17
Operating Cash Flow	-7	-14	-13	-10
Investing Cash Flow	0	-21	-	-
Financing Cash Flow	59	9	5	87
Change in Cash	47	-5	-8	76

Insights on Palvella Therapeutics, Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

POSITIVE IMPACT
Best in 1 Year
In the last 1 year, PVLA has outperformed top 5 stocks with highest market-cap in its industry
POSITIVE IMPACT
Price Rise
In the last 7 days, PVLA stock has moved up by 4.9%
NO EFFECT
Against Peers
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 153.0% return, outperforming this stock by 161.1%
NEGATIVE IMPACT
Profit Down
Netprofit is down for the last 3 quarters, -2.88M → -9.47M (in $), with an average decrease of 99.6% per quarter
NEGATIVE IMPACT
Revenue Fall
Revenue is down for the last 4 quarters, 20.05M → 53.0K (in $), with an average decrease of 64.0% per quarter

About Palvella Therapeutics, Inc.

Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. The Company is developing a pipeline of product candidates based on its patented QTORIN platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Its QTORIN product candidates are developed to accommodate the cargo at high concentrations in order to drive sufficient drug to its target deep in the epidermis and dermis. The Company's lead product candidate, QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin), is being evaluated in the Phase III SELVA clinical trial in microcystic lymphatic malformations and the Phase II TOIVA clinical trial in cutaneous venous malformations.

Organisation	Palvella Therapeutics, Inc.
Headquarters	125 Strafford Avenue, Wayne, PA, United States, 19087
CEO	Mr. Wesley H. Kaupinen
E-voting on shares	Click here to vote

Key Management of Palvella Therapeutics, Inc.

Name	Title
Mr. Wesley H. Kaupinen	Founder, President, CEO & Director
Dr. Jeffrey Martini Ph.D.	Chief Scientific Officer
Ms. Emily Cook	Senior Vice President of Clinical Operations
Mr. Jason Burdette	SVP of CMC & Technical Operations
Ms. Kathleen Goin	Chief Operating Officer
Mr. Matthew E. Korenberg	CFO & Treasurer
Ms. Bohan Wei	Vice President of Corporate Development & New Product Planning
Ms. Ashley Kline	Chief Commercial Officer
Dr. David W. Osborne Ph.D.	Chief Innovation Officer

FAQs

What is Palvella Therapeutics, Inc. share price today?

Palvella Therapeutics, Inc. share price today is $76.34 as on October 16, 2025 at 1:29 am IST at the close of the market. Palvella Therapeutics, Inc. share today touched a day high of $77.67 and a low of $73.55.

What is the 52 week high and 52 week low for Palvella Therapeutics, Inc. share?

Palvella Therapeutics, Inc. share touched a 52 week high of $77.67 on October 15, 2025 and a 52 week low of $11.17 on December 30, 2024. Palvella Therapeutics, Inc. stock price today i.e. October 16, 2025 at 1:29 am IST is closed at $76.34,which is 1.71% down from its 52 week high and 583.44% up from its 52 week low.

What is Palvella Therapeutics, Inc.'s market capitalisation today?

Palvella Therapeutics, Inc. market capitalisation is $0.00T as on October 16, 2025 at 1:29 am IST.

How to invest in Palvella Therapeutics, Inc. Stock (PVLA) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Palvella Therapeutics, Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Palvella Therapeutics, Inc. Shares that will get you 0.0196 shares as per Palvella Therapeutics, Inc. share price of $76.34 per share as on October 16, 2025 at 1:29 am IST.

What is the minimum amount required to buy Palvella Therapeutics, Inc. Stock (PVLA) from India?

Indian investors can start investing in Palvella Therapeutics, Inc. (PVLA) shares with as little as ₹87.985 or $1 (as of October 16, 2025 at 10:43 am IST) using the INDmoney app.
For example: If you want to invest $10 or ₹879.85 in Palvella Therapeutics, Inc. stock (as per the Rupee-Dollar exchange rate as on October 16, 2025 at 10:43 am IST). Based on Palvella Therapeutics, Inc. share’s latest price of $76.34 as on October 16, 2025 at 1:29 am IST, you will get 0.1310 shares of Palvella Therapeutics, Inc.. Learn more about fractional shares .